WO2017145096A3 - Virus recombinante de la enfermedad de newcastle que expresa una proteína inmunomoduladora como adyuvante molecular - Google Patents

Virus recombinante de la enfermedad de newcastle que expresa una proteína inmunomoduladora como adyuvante molecular Download PDF

Info

Publication number
WO2017145096A3
WO2017145096A3 PCT/IB2017/051053 IB2017051053W WO2017145096A3 WO 2017145096 A3 WO2017145096 A3 WO 2017145096A3 IB 2017051053 W IB2017051053 W IB 2017051053W WO 2017145096 A3 WO2017145096 A3 WO 2017145096A3
Authority
WO
WIPO (PCT)
Prior art keywords
newcastle disease
disease virus
recombinant newcastle
post
immune response
Prior art date
Application number
PCT/IB2017/051053
Other languages
English (en)
French (fr)
Other versions
WO2017145096A2 (es
Inventor
Angel Eduardo ABSALÓN CONSTANTINO
Diana Verónica CORTES ESPINOSA
Alejandra GALIOTE FLORES
Eduardo Lucio Decanini
Arnulfo TOSCANO CONTRERAS
Original Assignee
Investigación Aplicada S.A. de C.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Investigación Aplicada S.A. de C.V. filed Critical Investigación Aplicada S.A. de C.V.
Priority to CN201780025360.9A priority Critical patent/CN109195613A/zh
Priority to US16/079,975 priority patent/US20190134188A1/en
Priority to PE2018001566A priority patent/PE20190222A1/es
Publication of WO2017145096A2 publication Critical patent/WO2017145096A2/es
Publication of WO2017145096A3 publication Critical patent/WO2017145096A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a Virus de la Enfermedad de Newcastle recombinantes (NDVr's) que llevan inserta una unidad transcripcional ajena a su genoma, la cual codifica para la síntesis de interferón gamma. Estos sistemas ofrecen excelentes resultados de protección y disminuyen significativamente la carga viral excretada (post- vacunación y post-desafío) en aves inmunizadas varias semanas después de ser desafiadas con una cepa velogénica del Virus de Newcastle. Adicionalmente, dichas vacunas permiten la protección de aves contra otros agentes patógenos durante un largo periodo de tiempo ya que inducen un aumento de los niveles de las proteínas inmunomoduladoras, lo que se traduce en una potenciación de la respuesta inmune del hospedero y la promoción de una eficiente respuesta humoral y celular.
PCT/IB2017/051053 2016-02-24 2017-02-24 Virus recombinante de la enfermedad de newcastle que expresa una proteína inmunomoduladora como adyuvante molecular WO2017145096A2 (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201780025360.9A CN109195613A (zh) 2016-02-24 2017-02-24 作为分子佐剂的表达免疫调节蛋白的重组新城疫病毒
US16/079,975 US20190134188A1 (en) 2016-02-24 2017-02-24 Recombinant Newcastle Disease Virus Expressing an Immunomodulatory Protein as a Molecular Adiuvant
PE2018001566A PE20190222A1 (es) 2016-02-24 2017-02-24 Virus recombinante de la enfermedad de newcastle que expresa una proteina inmunomoduladora como adyuvante molecular

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2016002399A MX2016002399A (es) 2016-02-24 2016-02-24 Virus recombinante de la enfermedad de newcastle que expresa una proteina inmunomoduladora como adyuvante molecular.
MXMX/A/2016/002399 2016-02-24

Publications (2)

Publication Number Publication Date
WO2017145096A2 WO2017145096A2 (es) 2017-08-31
WO2017145096A3 true WO2017145096A3 (es) 2017-11-09

Family

ID=59685995

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/051053 WO2017145096A2 (es) 2016-02-24 2017-02-24 Virus recombinante de la enfermedad de newcastle que expresa una proteína inmunomoduladora como adyuvante molecular

Country Status (6)

Country Link
US (1) US20190134188A1 (es)
CN (1) CN109195613A (es)
CL (1) CL2018002333A1 (es)
MX (1) MX2016002399A (es)
PE (1) PE20190222A1 (es)
WO (1) WO2017145096A2 (es)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BINJAWADAGI, B. ET AL.: "Immunomodulatory effect of recombinant chicken interferon-gamma (rchIFN-y) on specific and non-specific immune responses in chicken vaccinated against Newcastle disease virus (NDV)", INTERNATIONAL JOURNAL OF POULTRY SCIENCE, vol. 8, no. 2, 2009, pages 122 - 127, XP055601781, ISSN: 1682-8356, DOI: 10.3923/ijps.2009.122.127 *
CARDENAS-GARCIA, S. ET AL.: "Effects of chicken interferon gamma on Newcastle disease virus vaccine immunogenicity", PLOS ONE, vol. 11, no. 7, 13 July 2016 (2016-07-13), pages e0159153-1 - e0159153-19, XP055537295, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0159153 *
KWON, J.-S. ET AL.: "Immune responses and pathogenesis in immunocompromised chickens in response to infection with the H9N2 low pathogenic avian influenza virus", VIRUS RESEARCH, vol. 133, no. 2, February 2008 (2008-02-01), pages 187 - 194, XP022559849, ISSN: 0168-1702 *
RAUTENSCHLEIN, S. ET AL.: "Embryo vaccination of turkey s against Newcastle disease infection with recombinant fowlpox virus constructs containing interferons as adjuvants", VACCINE, vol. 18, no. 5-6, 2000, pages 426 - 433, XP002168300, ISSN: 0264-410X, DOI: 10.1016/S0264-410X(99)00254-6 *
SUSTA, L. ET AL.: "Expression of interferon gamma by a highly virulent strain of Newcastle disease virus decreases its pathogenicity in chickens", MICROBIAL PATHOGENESIS, vol. 61 - 62, August 2013 (2013-08-01), pages 73 - 83, XP028596224, ISSN: 0882-4010, DOI: doi:10.1016/j.micpath.2013.05.009 *

Also Published As

Publication number Publication date
US20190134188A1 (en) 2019-05-09
PE20190222A1 (es) 2019-02-13
WO2017145096A2 (es) 2017-08-31
CL2018002333A1 (es) 2019-01-11
MX2016002399A (es) 2017-08-23
CN109195613A (zh) 2019-01-11

Similar Documents

Publication Publication Date Title
WO2020060403A3 (en) African swine fever virus vaccine
RU2018130813A (ru) Вакцины против fmdv на основе рекомбинантного аденовирусного вектора и их применение
JP2017530124A5 (es)
RU2017113571A (ru) Рекомбинантные вакцины от fmdv и их применение
RU2015132962A (ru) Иммуногенные композиции на основе вируса гриппа и их применение
RU2018116857A (ru) Мультивалентные рекомбинантные вирусы птичьего герпеса и вакцины для иммунизации птиц
EP3156070A3 (en) Newcastle disease virus vectored herpesvirus vaccines
HRP20190525T4 (hr) Rekombinantni vektori gallid herpesvirusa 3 (mdv serotip 2) koji eksprimiraju antigene ptičjih patogena i njihove uporabe
EP1298139A3 (en) Avian herpes virus-based recombinant infectious bursal disease vaccine
RU2016137119A (ru) Птичьи вирусные вакцины, которые являются стабильными в жидкой среде
RU2012114483A (ru) Вирусоподобные частицы, содержащие белки-мишени, слитые с белками оболочки растительных вирусов
RU2015138530A (ru) Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа
RU2016112465A (ru) Рекомбинантная вакцина на основе парамиксовирусов птиц и способ её приготовления и применения
BRPI0816134A2 (pt) Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença.
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
RU2018122755A (ru) Слитые белки fmdv-e2 и их применение
WO2017044895A3 (en) MVA-gH/gL-PC VACCINE DERIVED ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS INFECTIVITY AND METHODS THEREOF
Sautto et al. Next generation vaccines for infectious diseases
JP7046014B2 (ja) 伝染性喉頭気管炎ウイルスおよび伝染性ファブリキウス嚢病ウイルスの抗原をコードする組換え非病原性マレック病ウイルスコンストラクト
WO2005046621A3 (en) Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines
WO2017145096A3 (es) Virus recombinante de la enfermedad de newcastle que expresa una proteína inmunomoduladora como adyuvante molecular
EA201401044A1 (ru) Модифицированный вирус болезни марека и вакцины на его основе
KR101863335B1 (ko) 어류 바이러스성 출혈성 패혈증에 대한 예방 또는 치료용 dna 백신
Dhanwani et al. Arenaviral vaccine vectors to combat infectious diseases
TH141649A (th) รีคอมบิแนนท์เวกเตอร์เฮอร์ปีส์ไวรัสของสัตว์ปีกและวัคซีนสำหรับการก่อภูมิคุ้มกันสปีชีส์ของนกน้ำ

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 001566-2018

Country of ref document: PE

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17755924

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 17755924

Country of ref document: EP

Kind code of ref document: A2